What are the various FANA (fluorescent antinuclear antibody) staining patterns and their associated autoimmune disease associations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

FANA Staining Patterns and Disease Associations

The indirect immunofluorescence assay (IIFA) on HEp-2 cells remains the gold standard reference method for ANA detection, and laboratories must report both the titer and specific staining pattern, as pattern recognition provides critical diagnostic information that guides reflex testing and clinical interpretation 1.

Most Commonly Recognized Nuclear Patterns

Homogeneous Pattern

  • Target antigens: dsDNA, histones, chromatin/nucleosomes, HMG proteins
  • Associated diseases: SLE, drug-induced lupus/vasculitis, juvenile idiopathic arthritis
  • Clinical significance: This pattern shows the strongest association with disease activity markers in SLE, including high anti-dsDNA titers, low C3 levels, and positive direct Coombs test 2. When combined with nucleolar pattern (mixed pattern), it predicts increased risk of renal involvement in SLE 3

Coarse Speckled Pattern

  • Target antigens: U1-SnRNP, U2-6 snRNP (Sm), nuclear matrix proteins
  • Associated diseases: Mixed connective tissue disease (MCTD), SLE, Raynaud's phenomenon, systemic sclerosis, Sjögren's syndrome, undifferentiated connective tissue disease
  • Clinical note: Quantitative anti-RNP antibody determination is recommended when MCTD is clinically suspected 1

Fine Speckled Pattern

  • Target antigens: SSA/Ro, SSB/La, Topo-1, and many other antigens
  • Associated diseases: SLE, Sjögren's syndrome, systemic sclerosis, inflammatory myopathies, MCTD
  • Most common pattern: Represents 52.9% of SLE cases in recent studies 2
  • Critical caveat: Anti-SSA/Ro antibodies should be tested regardless of ANA result in suspected congenital heart block, neonatal lupus, or subacute cutaneous lupus, as these can be ANA-negative by IIFA 1

Centromere Pattern

  • Target antigens: Kinetochore proteins (CENP-A, B, C, F)
  • Associated diseases: Limited systemic sclerosis, Raynaud's phenomenon
  • Pattern recognition: Discrete speckled dots throughout interphase nuclei

Nucleolar Pattern

  • Target antigens: PM/Scl, RNA-polymerase, URNP, U3-RNP, To/Th, B23 phosphoprotein
  • Associated diseases: Systemic sclerosis, Raynaud's phenomenon, inflammatory myopathies, overlap syndromes
  • Clinical significance: When combined with homogeneous pattern, associated with 46.2% prevalence of renal involvement in SLE 3

Cytoplasmic Patterns (Often Overlooked but Clinically Important)

Diffuse Cytoplasmic

  • Target antigens: Ribosomal P protein (RibP), Jo-1, other tRNA synthetases, signal recognition particle (SRP)
  • Associated diseases: SLE, inflammatory myopathies
  • Frequency: Solitary cytoplasmic patterns occur in 2.0% of positive samples 4

Fine Speckled Cytoplasmic (Reticular)

  • Target antigens: Jo-1, SRP, pyruvate dehydrogenase (mitochondria - M2)
  • Associated diseases: Inflammatory myopathies, dermatomyositis, primary biliary cholangitis, interstitial lung disease
  • Clinical correlation: Most frequent cytoplasmic pattern; in PBC, 66.7% show anti-M2 antibodies 4

Dense Fine Speckled Cytoplasmic

  • Target antigens: Nucleosome, ribosomal P0
  • Associated diseases: Most frequently SLE (69.4% of cases with this pattern)
  • Antibody profile: 57.7% positive for anti-nucleosome, 53.8% for anti-ribosomal P0 4

Less Common but Diagnostically Significant Patterns

Peripheral/Rim Pattern

  • Target antigens: Lamins, LAP1/2, gp210, nucleoporin p62
  • Associated diseases: SLE, rheumatoid arthritis, primary biliary cirrhosis, inflammatory myopathies

Dense Fine Speckled (DFS70)

  • Target antigen: DFS70/LEDGF-P75
  • Clinical significance: Found in healthy subjects and non-autoimmune inflammatory conditions; helps exclude systemic autoimmune disease 1

Multiple Nuclear Dots

  • Target antigens: Sp100, PML bodies, p80-coilin
  • Associated diseases: Primary biliary cirrhosis, chronic autoimmune hepatitis, Sjögren's syndrome
  • Clinical note: At higher titers, strongly associated with autoimmune liver disease 5

Cell Cycle-Related Patterns

  • Patterns include: PCNA, centrosome/centriole, mitotic spindle apparatus (MSA/NuMA)
  • Clinical significance: Important non-autoimmune cause is carcinoma, particularly with rare cell-cycle related ANAs 5

Critical Clinical Pitfalls to Avoid

  1. Never assume ANA-negative excludes autoimmune disease: Anti-Jo-1, ribosomal P, and SS-A/Ro antibodies can be present in ANA-negative patients by IIFA. Request specific antibody testing when clinical suspicion is high, regardless of screening ANA result 1

  2. Multiple patterns increase diagnostic specificity: Patients with multiple FANA patterns (occurring in 46 of 4003 samples) show increased frequency of SLE and scleroderma spectrum diseases compared to single patterns 6. Homogeneous plus nucleolar is the most prevalent combination and warrants heightened clinical attention.

  3. Pattern recognition requires expertise: IIFA is only as good as the laboratory performing it. The substrate must contain sufficient mitotic cells for adequate pattern recognition, and technicians require continuous training 1

  4. Report patterns separately from titers: Both titer and pattern must be reported, as pattern provides independent diagnostic information that guides reflex testing 1

  5. Cytoplasmic patterns are clinically relevant: Do not dismiss cytoplasmic staining as non-specific. These patterns (3.4% of all positive samples) have specific disease associations and should trigger appropriate reflex testing 4

Algorithmic Approach to Pattern Interpretation

Step 1: Identify if pattern is nuclear, cytoplasmic, or mixed

  • Nuclear patterns → Consider SLE, MCTD, SSc, Sjögren's
  • Cytoplasmic patterns → Consider inflammatory myopathies, PBC
  • Mixed patterns → Higher risk of renal involvement in SLE 3

Step 2: Determine specific nuclear pattern subtype

  • Homogeneous → Reflex to anti-dsDNA, anti-histone
  • Speckled → Reflex to ENA panel (Sm, RNP, SSA, SSB, Scl-70)
  • Centromere → Consider limited SSc
  • Nucleolar → Consider diffuse SSc, overlap syndromes

Step 3: Correlate with clinical presentation

  • High clinical suspicion overrides negative screening results
  • Request specific antibodies based on clinical syndrome, not screening test alone 1

Step 4: Consider rare patterns and their implications

  • DFS70 → Likely non-autoimmune
  • Multiple nuclear dots (high titer) → Evaluate for autoimmune liver disease
  • Cell cycle patterns → Consider malignancy, especially carcinoma 5

References

Related Questions

What is cytoplasmic Antinuclear Antibody (ANA)?
What are the results of the Antinuclear Antibody (ANA) lab test?
In a patient with a low‑titer antinuclear antibody (ANA) of 1:80 showing a nucleolar pattern, a negative systemic autoimmune panel, elevated C‑reactive protein (CRP) of 18 mg/L, normal erythrocyte sedimentation rate (ESR), intermittent fatigue, nausea, blurry vision, headache, and metabolic syndrome, what is the clinical significance and what further evaluation and management are recommended?
What diagnosis and management should be considered for a patient with positive antinuclear antibody (ANA) showing a homogeneous pattern, prolonged partial thromboplastin time (PTT), elevated complement C3, and increased C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)?
What does an ANA HEp‑2 substrate test result mean, and how should the titer and staining pattern be interpreted?
What is the appropriate treatment for acute otitis media in a 7-year-old child weighing 42 lb (≈19 kg)?
What does an estimated glomerular filtration rate of 67 mL/min/1.73 m² indicate and what management steps are recommended?
How should a leflunomide (Arava) washout be performed?
What are the possible causes of pain just above the medial malleolus, and what evaluation and treatment steps are recommended?
Does tolerance develop to pregabalin (Lyrica)?
Should a tetanus toxoid (Tdap) booster be given to every patient after an animal bite, regardless of vaccination history?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.